Skip to main content

Invasive Fungal Infections

7
Pipeline Programs
12
Companies
9
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
1
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 11 programs with unclassified modality

On Market (2)

Approved therapies currently available

Pfizer
VFENDApproved
voriconazole
Pfizer
Azole Antifungal [EPC]intravenous2002
10K Part D
Pfizer
VORICONAZOLEApproved
voriconazole
Pfizer
oral2013

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
voriconazolePhase 4Small Molecule1 trial
Active Trials
NCT00288197Completed77Est. Jun 2007
Astellas
AstellasChina - Shenyang
3 programs
1
MicafunginPhase 31 trial
MicafunginN/A1 trial
MicafunginN/A1 trial
Active Trials
NCT03174457Completed120Est. May 2018
NCT02678598Completed2,555Est. Aug 2015
NCT00048750Terminated104Est. Jun 2003
F2G
F2GUK - Manchester
2 programs
1
1
OlorofimPhase 2
OlorofimPhase 11 trial
Active Trials
NCT04039880Completed12Est. Sep 2019
Biosergen
BiosergenSweden - Solna
1 program
1
BSG005 or placeboPhase 11 trial
Active Trials
NCT04921254Unknown72Est. May 2023
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
PET-CTN/A
PET-CTN/A
Eagle Pharmaceuticals
Eagle PharmaceuticalsNJ - Woodcliff Lake
1 program
Amphotericin B Liposome for InjectionN/A1 trial
Active Trials
NCT06977490Completed42Est. Oct 2025
Kite Pharma
Kite PharmaCA - El Segundo
1 program
PET-CTN/A1 trial
Active Trials
NCT05688592Recruiting224Est. Dec 2024
IQVIA
IQVIADURHAM, NC
1 program
OlorofimPHASE_21 trial
Active Trials
NCT03583164Completed203Est. Feb 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Pfizervoriconazole
AstellasMicafungin
IQVIAOlorofim
BiosergenBSG005 or placebo
F2GOlorofim
Eagle PharmaceuticalsAmphotericin B Liposome for Injection
Kite PharmaPET-CT
AstellasMicafungin
AstellasMicafungin

Clinical Trials (9)

Total enrollment: 3,409 patients across 9 trials

NCT00288197Pfizervoriconazole

A Study To Assess The Efficacy And Safety Of Voriconazole In Chinese Patients With Serious Deep Tissue Fungal Infections

Start: Jan 2006Est. completion: Jun 200777 patients
Phase 4Completed

Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

Start: Jan 2003Est. completion: Jun 2003104 patients
Phase 3Terminated

Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Start: Jun 2018Est. completion: Feb 2023203 patients
Phase 2Completed
NCT04921254BiosergenBSG005 or placebo

A Study to Assess the Safety, Tolerability and Pharmacokinetics of BSG005.

Start: Aug 2021Est. completion: May 202372 patients
Phase 1Unknown

Absorption, Metabolism and Excretion of 14C-olorofim in Man

Start: Jul 2019Est. completion: Sep 201912 patients
Phase 1Completed
NCT06977490Eagle PharmaceuticalsAmphotericin B Liposome for Injection

Human Bioequivalence Study of Amphotericin B Liposome for Injection

Start: May 2025Est. completion: Oct 202542 patients
N/ACompleted

Usefulness of PET-CT for Invasive Fungal Infection

Start: Apr 2023Est. completion: Dec 2024224 patients
N/ARecruiting

Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study

Start: Jun 2017Est. completion: May 2018120 patients
N/ACompleted

A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Start: Mar 2015Est. completion: Aug 20152,555 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 3,409 patients
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.